ALXO vs FDMT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ALXO Captures Institutional Edge (2โ1 Pillars ยท 3โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ALX Oncology Holdings Inc. Common Stock (ALXO) driven by superior Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, ALXO trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, ALXO sits in BREAKDOWN (20th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ALXO Revenue | FDMT Revenue | ALXO Op. Margin | FDMT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -662.0% | N/A | ALXO |
| FY2019 | $0M | $10M | -400.0% | -729.4% | ALXO |
| FY2020 | $0M | $10M | -3694.0% | -424.0% | FDMT |
| FY2021 | N/A | $20M | N/A | -395.5% | FDMT |
| FY2022 | N/A | $0M | N/A | -3516.5% | FDMT |
| FY2023 | N/A | $20M | N/A | -544.6% | FDMT |
| FY2024 | N/A | $0M | N/A | -507678.4% | FDMT |
| FY2025 | N/A | $90M | N/A | -187.2% | FDMT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ALXO | FDMT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $149.3M | $669.3M | Larger Scale | FDMT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +4505.6% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | 0.0% | -222.7% | Higher Margin | ALXO |
| Net Profit Margin Profitability | 0.0% | -208.6% | Higher Margin | ALXO |
| Return on Equity (ROE) Capital Efficiency | -80.7% | -56.7% | Higher ROE | FDMT |
| 52-Week Range Position Momentum | 5% ($1โ$3) | 47% ($7โ$17) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 1.46ฮฒ ยท 117% Vol | 1.89ฮฒ ยท 90% Vol | Lower Realized Risk | FDMT |
| Unified Institutional Score Composite Signal | 63.1 / 100 (BUY) | 51.3 / 100 (HOLD) | Higher Composite | ALXO |